Assessment of outcome of an ADHD treatment program using parent feedback

Perera, Hemamali; Jeewandara, Kamal Chandima; Seneviratne, Sudharshi; Guruge, Chandima

doi:10.4038/sljpsyc.v1i2.2575

Cited by 3 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20 A positive effect of o3 and o6 in reducing impulsivity and aggression has also been reported in other studies. 19,29 Limitations Including a crossover component was not possible as the trial was confined to a period of 6 months. The turnover of fatty acids in neural membrane is slow and needs a longer trial to make a crossover design appropriate.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Combined ω3 and ω6 Supplementation in Children With Attention-Deficit Hyperactivity Disorder (ADHD) Refractory to Methylphenidate Treatment

et al. 2012

Self Cite

View full text Add to dashboard Cite

Children (6-12 years) with attention-deficit hyperactivity disorder (ADHD) being treated with methylphenidate and standard behavior therapy for more than 6 months, whose parents reported no improvement in behavior and academic learning, were randomly assigned to receive supplementation with a combined ω3 and ω6 preparation or a placebo. Outcome was measured at 3 and 6 months after treatment using a self-assessment checklist completed by the parents. Statistically significant improvement was found in the treatment group compared with the placebo group (P < .01) in the following measures: restlessness, aggressiveness, completing work, and academic performance. Statistically significant improvement was not found at 3 months of treatment between groups but was evident at 6 months of treatment (P < .05) with inattention, impulsiveness, and cooperation with parents and teachers. Distractibility failed to show improvement. Effect sizes ranged from 0.3 to 1.1 at 3 months and 0.2 to 1.4 at 6 months for individual symptom variables.

show abstract

Section: Discussionmentioning

confidence: 99%

“…20 A positive effect of ω3 and ω6 in reducing impulsivity and aggression has also been reported in other studies. 19,29…”

Section: Discussionmentioning

confidence: 99%

Combined ω3 and ω6 Supplementation in Children With Attention-Deficit Hyperactivity Disorder (ADHD) Refractory to Methylphenidate Treatment

et al. 2012

Self Cite

View full text Add to dashboard Cite

show abstract

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies

Storebø

Pedersen

Ramstad

et al. 2018

Cochrane Database of Systematic Reviews

244

161

View full text Add to dashboard Cite

Our findings suggest that methylphenidate may be associated with a number of serious adverse events as well as a large number of non-serious adverse events in children and adolescents, which often lead to withdrawal of methylphenidate. Our certainty in the evidence is very low, and accordingly, it is not possible to accurately estimate the actual risk of adverse events. It might be higher than reported here.Given the possible association between methylphenidate and the adverse events identified, it may be important to identify people who are most susceptible to adverse events. To do this we must undertake large-scale, high-quality RCTs, along with studies aimed at identifying responders and non-responders.

show abstract

Which polyunsaturated fatty acids are active in children with attention-deficit hyperactivity disorder receiving PUFA supplementation? A fatty acid validated meta-regression analysis of randomized controlled trials

Puri

Martins²

2014

Prostaglandins, Leukotrienes and Essential Fatty Acids

View full text Add to dashboard Cite

Assessment of outcome of an ADHD treatment program using parent feedback

Cited by 3 publications

References 20 publications

Combined ω3 and ω6 Supplementation in Children With Attention-Deficit Hyperactivity Disorder (ADHD) Refractory to Methylphenidate Treatment

Combined ω3 and ω6 Supplementation in Children With Attention-Deficit Hyperactivity Disorder (ADHD) Refractory to Methylphenidate Treatment

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies

Which polyunsaturated fatty acids are active in children with attention-deficit hyperactivity disorder receiving PUFA supplementation? A fatty acid validated meta-regression analysis of randomized controlled trials

Contact Info

Product

Resources

About